ASCO GU Bladder Updates: EV-302, CheckMate 274, and More

By Karine Tawagi, MD, Samantha Armstrong, MD - Last Updated: February 24, 2025

Drs. Karine Tawagi and Samantha Armstrong, known together as “The Two Onc Docs,” provide relevant detail and discussion on the bladder cancer updates of note from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.

They spend considerable time on the latest EV-302 update, as well as long-term data from CheckMate 274.

Post Tags:ASCO GU Symposium 2025: Focus on Bladder Cancer

BRAVO Study: Blue Light Cystoscopy Reduces Recurrence in Patients With NMIBC

Emily MenendezUrothelial Carcinoma Diagnostics | March 20, 2025

Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.

Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025

The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.

Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.

ASCO GU Bladder Updates: EV-302, CheckMate 274, and More

Related Posts